“Alkyne as a Latent Warhead to Covalently Target SARS-CoV‑2 Main Protease”. Article review

We are all aware of the impact of the COVID-19 pandemic generated by the SARS-CoV-2 virus on the pharmaceutical sector. It appears to be a thing of the past, with essentially no new information about SARS-CoV-2 available in the public domain. However, issues continue to occur as a result of novel viral varieties and limits in existing immunization techniques. Despite tremendous progress in vaccine research, questions about their efficacy against novel viral varieties and the vulnerability of specific populations, such as immunocompromised people, remain. As a result, the emphasis is on the development of antiviral medications that target the SARS-CoV-2 main protease (Mpro), a critical enzyme in the virus's reproduction cycle. Mpro is a protein that is involved in the processing of viral polyproteins and is thought to be a prospective therapeutic target.